Comparison of gene expression in cell culture to that in the intact animal: Relevance to drugs and environmental toxicants. Focus on "Development of a transactivator in hepatoma cells that allows expression of phase I, phase II, and chemical defense genes"

American Journal of Physiology - Cell Physiology

Volumn 290, Issue 1, 2006, Pages

  Nebert, Daniel W ^a  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; DRUG METABOLIZING ENZYME; GLUTATHIONE TRANSFERASE; XENOBIOTIC AGENT;

CELL CULTURE; CELL SPECIFICITY; DRUG METABOLISM; EDITORIAL; GENE EXPRESSION; HEPATOMA CELL; METABOLIC ACTIVATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANIMAL; ANIMAL MODEL; COMPARATIVE STUDY; CYTOLOGY; DANGEROUS GOODS; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LIVER; LIVER CELL CARCINOMA; LIVER TUMOR; NOTE; PHYSIOLOGY; TUMOR CELL LINE;

ANIMALIA;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELLS, CULTURED; GENE EXPRESSION REGULATION, NEOPLASTIC; HAZARDOUS SUBSTANCES; HUMANS; LIVER; LIVER NEOPLASMS; MODELS, ANIMAL; XENOBIOTICS;

EID: 33644827547     PISSN: 03636143     EISSN: 15221563     Source Type: Journal    
DOI: 10.1152/ajpcell.00444.2005     Document Type: Editorial

References (47)

1. Bernhard HP, Darlington GJ, and Ruddle FH. Expression of liver phenotypes in cultured mouse hepatoma cells: synthesis and secretion of serum albumin. Dev Biol 35: 83-96, 1973.
2. Buters JT, Mahadevan B, Quintanilla-Martinez L, Gonzalez FJ, Greim H, Baird WM, and Luch A. Cytochrome P450 1B1 determines susceptibility to dibenzo[a,l]pyrene-induced tumor formation. Chem Res Toxicol 15: 1127-1135, 2002.
3. Buters JT, Sakai S, Richter T, Pineau T, Alexander DL, Savas U, Doehmer J, Ward JM, Jefcoate CR, and Gonzalez FJ. Cytochrome P450 CYP1B1 determines susceptibility to 7,12-dimethylbenz[a]anthracene-induced lymphomas. Proc Natl Acad Sci USA 96: 1977-1982, 1999.
4. Cheung C, Ma X, Krausz KW, Kimura S, Feigenbaum L, Dalton TP, Nebert DW, Idle JR, and Gonzalez FJ. Differential metabolism of 2-amino-1-methyl-6- phenylimidazol[4,5-b]pyridine (PhIP) in mice humanized for CYP1A1 and CYP1A2. Chem Res Toxicol 17: 1667-1674, 2005.
5. Derkenne S, Curran CP, Shertzer HG, Dalton TP, Dragin N, and Nebert DW. Theophylline pharmacokinetics: comparison of Cyp1a1(-/-) and Cyp1a2(-/-) knockout mice, humanized hCYP1A1_1A2 knock-in mice lacking either the mouse Cyp1a1 or Cyp1a2 gene, and Cyp1(+/+) wild-type mice. Pharmacogenet Genomics 15: 503-511, 2005.
6. Eaton DL, Gallagher EP, Bammler TK, and Kunze KL. Role of cytochrome P450 1A2 in chemical carcinogenesis: implications for human variability in expression and enzyme activity. Pharmacogenetics 5: 259-274, 1995.
7. Fernandez-Salguero PM, Hilbert DM, Rudikoff S, Ward JM, and Gonzalez FJ. Aryl-hydrocarbon receptor-deficient mice are resistant to 2,3,7,8- tetrachlorodibenzo-p-dioxin-induced toxicity. Toxicol Appl Pharmacol 140: 173-179, 1996.
8. Forster K, Helbl V, Lederer T, Urlinger S, Wittenburg N, and Hillen W. Tetracycline-inducible expression systems with reduced basal activity in mammalian cells. Nucleic Acids Res 27: 708-710, 1999.
9. Freundlieb S, Schirra-Muller C, and Bujard H. A tetracycline controlled activation/repression system with increased potential for gene transfer into mammalian cells. J Gene Med 1: 4-12, 1999.
10. Furth PA, St Onge L, Boger H, Gruss P, Gossen M, Kistner A, Bujard H, and Hennighausen L. Temporal control of gene expression in transgenic mice by a tetracycline-responsive promoter. Proc Natl Acad Sci USA 91: 9302-9306, 1994.
11. Goldring CEP, Kitteringham NR, Jenkins R, Lovatt CA, Randle LE, Abdullah A, Owen A, Liu X, Butler PJ, Williams DP, Metcalfe P, Berens C, Hillen W, Foster B, Simpson A, McLellan L, and Park BK. Development of a transactivator in hepatoma cells that allows expression of phase I, phase II, and chemical defense genes. Am J Physiol Cell Physiol 290: C104-C115, 2006.
12. Gossen M and Bujard H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci USA 89: 5547-5551, 1992.
13. Gossen M, Freundlieb S, Bender G, Muller G, Hillen W, and Bujard H. Transcriptional activation by tetracyclines in mammalian cells. Science 268: 1766-1769, 1995.
14. Guengerich FP, Chun YJ, Kim D, Gillam EM, and Shimada T. Cytochrome P450 1B1: a target for inhibition in anticarcinogenesis strategies. Mutat Res 523-524: 173-182, 2003.
15. Hankinson O. The aryl hydrocarbon receptor complex. Annu Rev Pharmacol Toxicol 35: 307-340, 1995.
16. Hankinson O. Single-step selection of clones of a mouse hepatoma line deficient in aryl hydrocarbon hydroxylase. Proc Natl Acad Sci USA 76: 373-376, 1979.
17. Jiang ZW, Dalton TP, Jin L, Wang B, Tsuneoka Y, Shertzer HG, Deka R, and Nebert DW. Toward the evaluation of function in genetic variability: characterizing human SNPs and establishing BAC-transgenic mice carrying the human CYP1A1_CYP1A2 locus. Hum Mutat 25: 196-206, 2005.
18. Katoh M, Matsui T, Nakajima M, Tateno C, Kataoka M, Soeno Y, Horie T, Iwasaki K, Yoshizato K, and Yokoi T. Expression of human cytochromes P450 in chimeric mice with humanized liver. Drug Metab Dispos 32: 1402-1410, 2004.
19. Katoh M, Matsui T, Nakajima M, Tateno C, Soeno Y, Horie T, Iwasaki K, Yoshizato K, and Yokoi T. In vivo induction of human cytochrome P450 enzymes expressed in chimeric mice with humanized liver. Drug Metab Dispos 33: 754-763, 2005.
20. Katoh M, Matsui T, Okumura H, Nakajima M, Nishimura M, Naito S, Tateno C, Yoshizato K, and Yokoi T. Expression of human phase II enzymes in chimeric mice with humanized liver. Drug Metab Dispos 33: 1333-1340, 2005.
21. Kimura S, Kawabe M, Yu A, Morishima H, Fernandez-Salguero P, Hammons GJ, Ward JM, Kadlubar FF, and Gonzalez FJ. Carcinogenesis of the food mutagen PhIP in mice is independent of CYP1A2. Carcinogenesis 24: 583-587, 2003.
22. Kimura S, Kawabe M, Ward JM, Morishima H, Kadlubar FF, Hammons GJ, Fernandez-Salguero P, and Gonzalez FJ. CYP1A2 is not the primary enzyme responsible for 4-aminobiphenyl-induced hepatocarcinogenesis in mice. Carcinogenesis 20: 1825-1830, 1999.
23. Koponen JK, Kankkonen H, Kannasto J, Wirth T, Hillen W, Bujard H, and Yla-Herttuala S. Doxycycline-regulated lentiviral vector system with a novel reverse transactivator rtTA2S-M2 shows a tight control of gene expression in vitro and in vivo. Gene Ther 10: 459-466, 2003.
24. Nebert DW, Dalton TP, Okey AB, and Gonzalez FJ. Role of aryl hydrocarbon receptor-mediated induction of the CYP1 enzymes in environmental toxicity and cancer. J Biol Chem 279: 23847-23850, 2004.
25. Nebert DW and Jorge-Nebert LF. Pharmacogenetics and pharmacogenomics. In: Emery and Rimoin's Principles and Practice of Medical Genetics (4th ed.), edited by Rimoin DL, Connor JM, Pyeritz RE, and Korf BR. London: Churchill Livingstone, 2002, vol. I, p. 590-631.
26. Nebert DW, McKinnon RA, and Puga A. Human drug-metabolizing enzyme polymorphisms: effects on risk of toxicity and cancer. DNA Cell Biol 15: 273-280, 1996.
27. Nebert DW and Wain HM. Update on human genome completion and annotations: gene nomenclature. Hum Genomics 1: 66-71, 2003.
28. Nebert DW and Vesell ES. Advances in pharmacogenomics and individualized drug therapy: exciting challenges that lie ahead. Eur J Pharmacol 500: 267-280, 2004.
29. Newbold RF and Overell RW. Fibroblast immortality is a prerequisite for transformation by EJ c-Ha-ras oncogene. Nature 304: 648-651, 1983.
30. Owens IS, Niwa A, and Nebert DW. Expression of aryl hydrocarbon hydroxylase induction in liver- and hepatoma-derived cell cultures. In: Gene Expression and Carcinogenesis in Cultured Liver, edited by Gerschenson LE and Thompson EB. New York: Academic, 1975, p. 378-401.
31. Page TJ, O'Brien S, Holston K, MacWilliams PS, Jefcoate CR, and Czuprynski CJ. 7,12-Dimethylbenz[a]anthracene-induced bone marrow toxicity is p53-dependent. Toxicol Sci 74: 85-92, 2003.
32. Paul D, Hohne M, and Hoffmann B. Immortalization and malignant transformation of hepatocytes by transforming genes of polyoma virus and of SV40 virus in vitro and in vivo. Klin Wochenschr 66, Suppl 11: 134-139, 1988.
33. Pugh JC, Yaginuma K, Koike K, and Summers J. Duck hepatitis B virus (DHBV) particles produced by transient expression of DHBV DNA in a human hepatoma cell line are infectious in vitro. J Virol 62: 3513-3516, 1988.
34. Rojkind M, Gatmaitan Z, Mackensen S, Giambrone MA, Ponce P, and Reid LM. Connective tissue biomatrix: its isolation and utilization for long-term cultures of normal rat hepatocytes. J Cell Biol 87: 255-263, 1980.
35. Schwartz AL, Fridovich SE, Knowles BB, and Lodish HF. Characterization of the asialoglycoprotein receptor in a continuous hepatoma line. J Biol Chem 256: 8878-8881, 1981.
36. Seglen PO. Hepatocyte suspensions and cultures as tools in experimental carcinogenesis. J Toxicol Environ Health 5: 551-560, 1979.
37. Shertzer HG, Dalton TP, Talaska G, and Nebert DW. Decrease in 4-aminobiphenyl-induced methemoglobinemia in Cyp1a2(-/-) knockout mice. Toxicol Appl Pharmacol 181: 32-37, 2002.
38. Shimizu Y, Nakatsuru Y, Ichinose M, Takahashi Y, Kume H, Mimura J, Fujii-Kuriyama Y, and Ishikawa T. Benzo[a]pyrene carcinogenicity is lost in mice lacking the aryl hydrocarbon receptor. Proc Natl Acad Sci USA 97: 779-782, 2000.
39. Shockett P, Difilippantonio M, Hellman N, and Schatz DG. A modified tetracycline-regulated system provides autoregulatory, inducible gene expression in cultured cells and transgenic mice. Proc Natl Acad Sci USA 92: 6522-6526, 1995.
40. Snyderwine EG, Yu M, Schut HA, Knight-Jones L, and Kimura S. Effect of CYP1A2 deficiency on heterocyclic amine DNA adduct levels in mice. Food Chem Toxicol 40: 1529-1533, 2002.
41. Takeshita K, Bowen WC, and Michalopoulos GK. Three-dimensional culture of hepatocytes in a continuously flowing medium. In Vitro Cell Dev Biol Anim 34: 482-485, 1998.
42. Tateno C, Yoshizane Y, Saito N, Kataoka M, Utoh R, Yamasaki C, Tachibana A, Soeno Y, Asahina K, Hino H, Asahara T, Yokoi T, Furukawa T, and Yoshizato K. Near completely humanized liver in mice shows human-type metabolic responses to drugs. Am J Pathol 165: 901-912, 2004.
43. Tsuneoka Y, Dalton TP, Miller ML, Clay CD, Shertzer HG, Talaska G, Medvedovic M, and Nebert DW. 4-Amino-biphenyl-induced liver and urinary bladder DNA adduct formation in Cyp1a2(-/-) and Cyp1a2(+/+) mice. J Natl Cancer Inst 95: 1227-1237, 2003.
44. Uno S, Dalton TP, Derkenne S, Curran CP, Miller ML, Shertzer HG, and Nebert DW. Oral exposure to benzo[a]pyrene in the mouse: detoxication by inducible cytochrome P450 is more important than metabolic activation. Mol Pharmacol 65: 1225-1237, 2004.
45. Urlinger S, Baron U, Thellmann M, Hasan MT, Bujard H, and Hillen W. Exploring the sequence space for tetracycline-dependent transcriptional activators: novel mutations yield expanded range and sensitivity. Proc Natl Acad Sci USA 97: 7963-7968, 2000.
46. Yoon BI, Hirabayashi Y, Kawasaki Y, Kodama Y, Kaneko T, Kanno J, Kim DY, Fujii-Kuriyama Y, and Inoue T. Aryl hydrocarbon receptor mediates benzene-induced hematotoxicity. Toxicol Sci 70: 150-156, 2002.
47. Zabala M, Wang L, Hernandez-Alcoceba R, Hillen W, Qian C, Prieto J, and Kramer MG. Optimization of the Tet-on system to regulate interleukin-12 expression in the liver for treatment of hepatic tumors. Cancer Res 64: 2799-2804, 2004.